|
24 Sep 2009 |
Genzyme’s Campath Meets Primary Endpoint in Phase 3 Combination Therapy Trial for Chronic Lymphocytic Leukemia
|
|
24 Sep 2009 |
Vectibix(R) in Combination With Chemotherapy Significantly Improves Progression-Free Survival in First-Line Metastatic Colorectal Cancer
|
|
24 Sep 2009 |
Farletuzumab Data Presented on Phase II Clinical Trial in First-Relapsed Ovarian Cancer Subjects
|
|
23 Sep 2009 |
Erbitux Significantly Increases Survival in 1st-Line Metastatic Colorectal Cancer Patients
|
|
23 Sep 2009 |
Initial COIN Study Results Presented at European Oncology Congress
|
|
23 Sep 2009 |
BioInvent updates on the progress of the Phase II trial of the long acting anticoagulant TB-402
|
|
23 Sep 2009 |
Roche announces results from two early studies which show promise for patients with malignant melanoma
|
|
23 Sep 2009 |
ImmunoCellular Therapeutics Announces Successful Humanization of Two Antibody Candidates
|
|
22 Sep 2009 |
Denosumab Demonstrates Superiority Over Zometa(R) in Delay of Complications Due to Bone Metastases in Advanced Breast Cancer Patients
|
|
22 Sep 2009 |
Vectibix(R) in Combination With Chemotherapy Significantly Improves Progression-Free Survival in Second-Line Metastatic Colorectal Cancer
|
|
21 Sep 2009 |
Micromet Reports Interim Data from Phase 1 Study of BiTE Antibody MT110 for the Treatment of Solid Tumors
|
|
21 Sep 2009 |
Phase 3 Trial Shows Denosumab Delayed Skeletal Related Events in Advanced Cancer Patients With Bone Metastases
|
|
18 Sep 2009 |
Pancreatic and Colorectal Cancer Novel Antibody Developed from a Vaccine to Begin Phase I Trial
|
|
18 Sep 2009 |
ArmaGen completes primate safety study for AGT-181
|
|
17 Sep 2009 |
Alligator Bioscience enters into research and option agreement with BioInvent to jointly develop Antibody-based therapeutics for novel treatments for oncology indications
|
|
17 Sep 2009 |
Phase III Study Showed Patients Lived Longer Without Low-Grade Lymphoma Progressing When Rituxan Was Used First-Line for Maintenance
|
|
17 Sep 2009 |
ImmunoGen Announces Amgen has Licensed Rights to Use the Company's TAP Technology for a Solid Tumor Target
|
|
16 Sep 2009 |
Avaxia Biologics Awarded Phase I SBIR Grant to Develop Antibody Therapeutic for Oral Mucositis
|
|
15 Sep 2009 |
Kenta Biotech Reports Phase IIa Data with Lead Candidate Panobacumab in Hospital-Acquired Pneumonia
|
|
15 Sep 2009 |
Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (Wet AMD)
|
|
14 Sep 2009 |
Phase 3 Trial of Aflibercept in Metastatic Pancreatic Cancer Discontinued
|
|
11 Sep 2009 |
Genzyme’s Alemtuzumab for Multiple Sclerosis Shows Durable Treatment Benefit in Review of Four-Year Phase 2 Trial Data
|
|
09 Sep 2009 |
ImmunoCellular Therapeutics Enters into Research and License Option Agreement with Roche Group
|
|
09 Sep 2009 |
XOMA Announces $6 Million Antibody Discovery Collaboration With Arana Therapeutics
|
|
08 Sep 2009 |
MorphoSys Announces Clinical Milestone in Cancer Program with Bayer Schering Pharma
|
